KLP Kapitalforvaltning AS Invests $861,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

KLP Kapitalforvaltning AS bought a new stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 35,600 shares of the company's stock, valued at approximately $861,000.

Several other institutional investors and hedge funds have also modified their holdings of HIMS. Crewe Advisors LLC bought a new position in Hims & Hers Health in the 4th quarter valued at $28,000. Raleigh Capital Management Inc. increased its stake in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 1,100 shares in the last quarter. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after buying an additional 600 shares during the last quarter. Smartleaf Asset Management LLC lifted its position in Hims & Hers Health by 4,415.6% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Finally, US Bancorp DE grew its holdings in Hims & Hers Health by 346.7% during the 4th quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after acquiring an additional 1,508 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Trading Down 7.4 %

Shares of NYSE:HIMS traded down $2.06 during mid-day trading on Friday, reaching $25.93. The stock had a trading volume of 27,621,633 shares, compared to its average volume of 14,730,901. The firm has a 50 day simple moving average of $39.82 and a two-hundred day simple moving average of $29.94. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98. The firm has a market cap of $5.76 billion, a PE ratio of 58.93 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to analysts' expectations of $494.56 million. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on HIMS shares. Piper Sandler boosted their target price on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Leerink Partners boosted their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research report on Tuesday, February 25th. Citigroup reaffirmed a "sell" rating and set a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday, March 6th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Finally, Morgan Stanley lowered Hims & Hers Health from an "overweight" rating to an "equal weight" rating and upped their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $37.31.

Insider Activity

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the sale, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. The trade was a 21.58 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Soleil Boughton sold 3,236 shares of Hims & Hers Health stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $27.77, for a total transaction of $89,863.72. Following the completion of the sale, the insider now owns 170,285 shares in the company, valued at $4,728,814.45. This trade represents a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,078,738 shares of company stock worth $38,386,521 over the last quarter. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.